摘要
目的:探究卡瑞利珠单抗联合二线治疗在三阴性乳腺癌(TNBC)中的应用效果。方法:以广州中医药大学金沙洲医院2023年1月—2025年1月收治的102例TNBC患者为研究对象,以随机数字表法分为两组,各51例。对照组予以二线治疗(阿帕替尼+卡培他滨),在此基础上,研究组予以卡瑞利珠单抗治疗。以21 d为1个治疗周期,两组均治疗4个周期。统计两组疾病控制率、毒副反应发生率,比较治疗前、治疗4个周期后两组肿瘤标志物[胸苷激酶1(TK1)、癌胚抗原(CEA)、组织多肽特异性抗原(TPS)、糖类抗原125(CA125)]、免疫功能(CD4^(+),CD8^(+),CD4^(+)/CD8^(+))及凋亡抑制因子[环氧化酶-2(COX-2)、诱骗受体3(DcR3)]水平。结果:治疗4个周期后,研究组疾病控制率较对照组高(P<0.05)。与治疗前相比,两组治疗4个周期后的TPS、TK1、CEA、CA125水平低,且研究组低于对照组(P<0.05)。与治疗前相比,两组治疗4个周期后的COX-2、DcR3水平低,且研究组低于对照组(P<0.05)。与对照组相比,研究组治疗4个周期后的CD4^(+)、CD4^(+)/CD8^(+)高,CD8^(+)低(P<0.05)。两组贫血、高血压、中性粒细胞减少及白细胞减少发生率比较,差异无统计学意义(P>0.05)。结论:卡瑞利珠单抗联合二线治疗(阿帕替尼+卡培他滨)应用于TNBC患者可提高治疗效果,改善免疫功能,且不会增加毒副反应。
Objective:To explore the application effect of Camrelizumab combined with second-line therapy in triple negative breast cancer(TNBC).Method:A total of 102 TNBC patients admitted to Jinshazhou Hospital of Guangzhou University of Traditional Chinese Medicine from January 2023 to January 2025 were taken as the research objects and divided into two groups by random number table method,with 51 cases in each group.The control group was given second-line treatment(Apatinib+Capecitabine),and on this basis,the study group was given Camrelizumab treatment.With 21 days as one treatment cycle,both groups were treated for 4 cycles.The disease control rate and the incidence of toxic and side effects of the two groups were statistically analyzed.The levels of tumor markers[thymidine kinase 1(TK1),carcinoembryonic antigen(CEA),tissue polypeptide specific antigen(TPS),carbohydrate antigen 125(CA125)],immune function(CD4^(+),CD8^(+),CD4^(+)/CD8^(+))and apoptotic factors[cyclooxygenase-2(COX-2),decoy receptor 3(DcR3)]of the two groups were compared before treatment and after 4 cycles of treatment.Result:After 4 cycles of treatment,the disease control rate of the study group was higher than that of the control group(P<0.05).Compared with before treatment,the levels of TPS,TK1,CEA and CA125 in both groups after 4 cycles of treatment were lower,and those in the study group were lower than those in the control group(P<0.05).Compared with before treatment,the levels of COX-2 and DcR3 in both groups after 4 cycles of treatment were lower,and those in the study group were lower than those in the control group(P<0.05).Compared with the control group,the CD4^(+)and CD4^(+)/CD8^(+)levels in the study group after 4 cycles of treatment were higher,and the CD8^(+)levels was lower(P<0.05).There were no statistically significant differences in the incidence of anemia,hypertension,neutropenia and leukopenia between the two groups(P>0.05).Conclusion:Camrelizumab combined with second-line treatment(Apatinib+Capecitabine)in TNBC patients can enhance the therapeutic effect,improve immune function,and will not increase toxic and side effects.
作者
国滨
张远
董晶
徐振华
时桢
GUO Bin;ZHANG Yuan;DONG Jing;XU Zhenhua;SHI Zhen(Department of Tumor Radiotherapy,Jinshazhou Hospital of Guangzhou University of Traditional Chinese Medicine,Guangzhou 510168,China;不详)
出处
《中国医学创新》
2025年第36期14-18,共5页
Medical Innovation of China
